Carl Zeiss Meditec AG (XTER:AFX) EBIT : €270 Mil (TTM As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Carl Zeiss Meditec AG EBIT?

Carl Zeiss Meditec AG's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was €79 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was €270 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Carl Zeiss Meditec AG's annualized ROC % for the quarter that ended in Sep. 2024 was 1.61%. Carl Zeiss Meditec AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 50.28%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Carl Zeiss Meditec AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 6.08%.

Carl Zeiss Meditec AG EBIT Historical Data

The historical data trend for Carl Zeiss Meditec AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Carl Zeiss Meditec AG EBIT Chart

Carl Zeiss Meditec AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

EBIT

Get a 7-Day Free Trial

206.61

348.42

413.08

427.81

270.29

Carl Zeiss Meditec AG Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT	Get a 7-Day Free Trial															119.61	58.60	75.40	57.38	78.89

Competitive Comparison of Carl Zeiss Meditec AG's EBIT

For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Carl Zeiss Meditec AG's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Carl Zeiss Meditec AG's EV-to-EBIT falls into.

Carl Zeiss Meditec AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €270 Mil.

Carl Zeiss Meditec AG (XTER:AFX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Carl Zeiss Meditec AG's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	55.004 * ( 1 - 9.52% )	/	( (0	+	3091.991)	/ 1 )
=	49.7676192	/	3091.991
=	1.61 %

where

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3393.2	-	280.924	-	( 20.285	-	max(0, 568.835	-	1212.483	+	20.285	))
=	3091.991

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Carl Zeiss Meditec AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	315.56	/	( ( (0 + max(0, 0))	+	(353.763 + max(273.822, 0)) )	/	1 )
=	315.56	/	( ( 0	+	627.585 )	/	1 )
=	315.56	/	627.585
=	50.28 %

where Working Capital is:

	Working Capital		(Q: Jun. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(209.053	+	536.163	+	72.851)	-	(280.924	+	0	+	263.321)
=	273.822

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Carl Zeiss Meditec AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	270.265	/	4446.591
	=	6.08 %

Carl Zeiss Meditec AG EBIT Related Terms

Thank you for viewing the detailed overview of Carl Zeiss Meditec AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Carl Zeiss Meditec AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Carl Zeiss Meditec AG (XTER:AFX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

CZMWY:USA CZMWF:USA 1AFX:Italy AFXd:UK 0DHC:UK AFX:Austria

Address

Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745

Website

https://www.zeiss.com

Carl Zeiss Meditec is one of the largest medical technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up 75% of sales in 2022, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.

Carl Zeiss Meditec AG Headlines

No Headlines